Area of research
Hematology · Oncology
Research interest
Research focused on Eltrombopag and Azacitidine, with related work in Delphi method, Aplastic anemia, Tolerability. Notable publications include 'Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group–an observational analysis by the Acute...', 'Evidence-based expert consensus on clinical management of safety of Bruton’s tyrosine kinase inhibitors (2024)', and 'Comparison of efficacy of eltrombopag combined with immunosuppression in the treatment of severe aplastic anemia and very severe aplastic anemia: real-world data and evidence'.
Extracellular thiol isomerase ERp5 regulates integrin αIIbβ3 activation by inhibition of fibrinogen binding
Efficacy of venetoclax combined with homoharringtonine and cytarabine for younger adults with newly diagnosed AML
Mendelian randomization analysis of blood metabolites and immune cell mediators in relation to GVHD and relapse
KIF11 promotes AML progression, and its inhibition by SB-743921 suppresses disease advancement through mitotic G2/M phase arrest
Thiol isomerase ERp18 enhances platelet activation and arterial thrombosis
Venetoclax plus azacitidine in relapsed or refractory T-cell acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 trial
China Expert consensus on the application of metagenomic next-generation sequencing for the etiological diagnosis of infections in hematological disorders (2024)
Evidence-based expert consensus on clinical management of safety of Bruton’s tyrosine kinase inhibitors (2024)
Comparison of efficacy of eltrombopag combined with immunosuppression in the treatment of severe aplastic anemia and very severe aplastic anemia: real-world data and evidence
Switching from eltrombopag to hetrombopag in patients with primary immune thrombocytopenia: a post-hoc analysis of a multicenter, randomized phase III trial
CACA guidelines for holistic integrative management of adult acute myeloid leukemia
The C553-C581 Disulfide of Human Factor XI Is Crucial for Its Activation and Is Targeted By Thiol Isomerase Pdir
AK117 (anti-CD47 monoclonal antibody) in Combination with Azacitidine for Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS): AK117-103 Phase 1b Results
Expert consensus on microtransplant for acute myeloid leukemia in elderly patients -report from the international microtransplant interest group
Safety and performance of the<scp>S</scp>pectra<scp>O</scp>ptia apheresis system for white blood cell depletion in patients with elevated white blood cell counts
Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
The safety and performance of the Spectra Optia apheresis system platelet depletion protocol in patients with elevated platelet counts
A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome
2021 Chinese consensus on the diagnosis and management of primary immune thrombocytopenia in pregnancy
Bendamustine in the treatment of patients with indolent non‐Hodgkin lymphoma refractory or relapse to rituximab treatment: An open‐label, single‐agent, multicenter study in China
Switching from Eltrombopag to Hetrombopag in Patients with Primary Immune Thrombocytopenia (ITP): Post-Hoc Analysis of a Multicenter, Randomized Phase III Trial
The disulfide bond Cys2724-Cys2774 in the C-terminal cystine knot domain of von Willebrand factor is critical for its dimerization and secretion
Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytes
Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group–an observational analysis by the Acute Leukemia Working Party of the EBMT